MAPT and Alzheimer disease: Preliminary results reveal that (1) tACS can induce a significant induction of gamma activity in patients with AD that can be demonstrated on EEG; and (2) tACS-induced modulation of amyloid and tau deposition is demonstrable by PET, consistent with results in the murine models (ClinicalTrials NCT03412604).